In a significant development for the healthcare sector, the subcommittee of the Health Insurance Policy Deliberation Committee convened on August 17th to announce the outcomes of the inaugural re-바카라 드래곤 of upper limit amounts assigned to government-designated drugs. The results of this 바카라 드래곤 are expected to generate considerable financial benefits, with an estimated savings of around 3 million (300 billion won).
The assessment, carried out by the subcommittee, encompassed a comprehensive review of 16,720 items. This assessment excluded items earmarked for market expansion. Among these, a total of 9,046 items are slated to retain their existing upper limit amounts. This grouping comprises products that were part of the initial listing, alongside low-priced medications and items that were previously excluded from 바카라 드래곤. In contrast, prices for 7,677 items have been adjusted downward.
The recalibration of drug prices was contingent on the fulfillment of specific criteria, such as providing substantiated data on biological equivalence testing, clinical trial performance, and evidence of the utilization of registered raw materials in drug production. For items that fell short of meeting a single criterion, a 15% reduction in price will be applied to a total of 7,421 items. For those failing to meet two criteria, a steeper reduction of 27.75% will be implemented, impacting 256 items. The anticipated cumulative financial benefit resulting from these price adjustments is expected to reach 1.7 million (297.8 billion won).
Notably, the Health Insurance Review and Assessment Service (HIRA) received data pertaining to the criteria for the first-round target drugs until February. During the inaugural deliberation of the Drug Reimbursement 바카라 드래곤 Committee, it was resolved that the upper limit amount would remain unchanged for approximately 8,462 items. Subsequently, objections were raised by 167 companies in connection to 1,323 items. Following a meticulous review process, it was determined that roughly 65% of these objections, accounting for a total of 854 items, would lead to the maintenance of the existing upper limit amount.
These findings are poised to be disseminated through the deliberations of the Health Insurance Policy Deliberation Committee by the close of this month, with an official announcement scheduled for September 1st. Considering the requisite adjustments in pricing across pharmacies and other medical institutions, the revised pricing is anticipated to be implemented in early September.
Simultaneously, HIRA is embarking on a second-round re-바카라 드래곤 encompassing around 6,000 items. This 바카라 드래곤 includes orally administered formulations, injectables, and other components and formats subject to expanded obligations. Further updates on these proceedings are anticipated in due course.